These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28753792)

  • 1. Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
    Lorente D; Ravi P; Mehra N; Pezaro C; Omlin A; Gilman A; Miranda M; Rescigno P; Kolinsky M; Porta N; Bianchini D; Tunariu N; Perez R; Mateo J; Payne H; Terstappen L; IJzerman M; Hall E; de Bono J
    Eur Urol Focus; 2018 Mar; 4(2):235-244. PubMed ID: 28753792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
    Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
    Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
    De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
    Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
    Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
    Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
    Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
    Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
    Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
    Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N
    Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
    Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
    Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
    Kosaka T; Hongo H; Oya M
    BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.
    Antonarakis ES; Tagawa ST; Galletti G; Worroll D; Ballman K; Vanhuyse M; Sonpavde G; North S; Albany C; Tsao CK; Stewart J; Zaher A; Szatrowski T; Zhou W; Gjyrezi A; Tasaki S; Portella L; Bai Y; Lannin TB; Suri S; Gruber CN; Pratt ED; Kirby BJ; Eisenberger MA; Nanus DM; Saad F; Giannakakou P;
    J Clin Oncol; 2017 Oct; 35(28):3181-3188. PubMed ID: 28632486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
    BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.
    Climent MÁ; Pérez-Valderrama B; Mellado B; Fernández Parra EM; Fernández Calvo O; Ochoa de Olza M; Muinelo Romay L; Anido U; Domenech M; Hernando Polo S; Arranz Arija JÁ; Caballero C; Juan Fita MJ; Castellano D
    Eur J Cancer; 2017 Dec; 87():30-37. PubMed ID: 29102858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
    Scher HI; Armstrong AJ; Schonhoft JD; Gill A; Zhao JL; Barnett E; Carbone E; Lu J; Antonarakis ES; Luo J; Tagawa S; Dos Anjos CH; Yang Q; George D; Szmulewitz R; Danila DC; Wenstrup R; Gonen M; Halabi S
    Eur J Cancer; 2021 Jun; 150():83-94. PubMed ID: 33894633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cells versus objective response assessment predicting survival in metastatic castration-resistant prostate cancer patients treated with docetaxel chemotherapy.
    Thalgott M; Heck MM; Eiber M; Souvatzoglou M; Hatzichristodoulou G; Kehl V; Krause BJ; Rack B; Retz M; Gschwend JE; Andergassen U; Nawroth R
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1457-64. PubMed ID: 25708944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial.
    Autio KA; Dreicer R; Anderson J; Garcia JA; Alva A; Hart LL; Milowsky MI; Posadas EM; Ryan CJ; Graf RP; Dittamore R; Schreiber NA; Summa JM; Youssoufian H; Morris MJ; Scher HI
    JAMA Oncol; 2018 Oct; 4(10):1344-1351. PubMed ID: 29978216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
    Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.